Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-352-0 | CAS number: 139-08-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
For the oral route, based on the effects observed in the 90-day read across study, the NOEL for the test substance, C14 ADBAC, can be considered to be at 500 ppm in the diet (i.e., equivalent to 31 mg/kg bw/day (or 25 mg a.i./kg bw/d) for males and 38 mg/kg bw/d (i.e. 30 mg a.i./kg bw/d) for females). With regard to the dermal route, a 20-day repeated dose dermal study available with C14 ADBAC in rabbits, revealed only local effects (severe erythema, oedema, thickening of the skin and eschar formation across the back) at the site of application without presence of any systemic effects. The NOAEL for systemic effects was therefore established at 3.2 mg/kg bw/day and the LOAEL for local effects at 0.8 mg/kg bw/day. However, due to some deficiencies in the study (e.g., reduced number of test animals per group), the 90-day oral study with the read across substance, C12-16 ADBAC, has been used for hazard assessment of systemic effects following repeated dosing via dermal route.
However, in line with the Biocides dossier on the read across substance, it can be concluded that there were no primary systemic effects observed in the repeated dose studies and all observed effects could be attributed to local gastrointestinal irritaton/corrosion and consequent reduced food intake. Therefore, the derivation of a DNEL for systemic effects via oral or dermal route has been deemed inappropriate.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- From June 18, 1987 to June 21, 1988
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- KL2 due to RA
- Justification for type of information:
- Refer to section 13 for details on the read-across justification. The study with the read across substance is considered sufficient to fulfil the information requirements as further explained in the provided endpoint summary.
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 82-1 (90-Day Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Test animals
- Source: Sprague-Dawley CD rats were obtained from Charles River Breeding Laboratories, Portage, MI, USA.
- Age at study initiation: 7 weeks
- Weight at study initiation: 221.6-250.9 g (males); 147.7-174.4 g (females)
- Housing: Animals were housed one animal/side of divided stainless steel cages (solid sides with wire mesh floors) mounted in a stainless steel Maxi-Rack (Hazleton Systems, Inc., Aberdeen, MD).
- Diet: Ground Purina Certified Rodent Chow # 5002 (Ralstor Purina Co., St. Louis, MO), ad libitum
- Water: Tap water, ad libitum. Water was provided by an automatic watering system with demand control valves mounted on each cage rack
- Acclimation period: 1 week
Environmental conditions:
- Temperature: 22 ± 3°C
- Humidity: 40-70%
- Photoperiod: 12h light/12h dark
In-life dates: From: 18 June 1987 to: 22 September 1987 - Route of administration:
- oral: feed
- Vehicle:
- other: Ground Purina Certified Rodent Chow # 5002
- Details on oral exposure:
- Diet preparation: Test diets were prepared by direct addition of the test substance to ground rodent feed. A concentrated premix was prepared to ensure maximal loss of the ethanol (approximately 12% by weight) from the test substance during the original mixing time of 1h. Test diets were prepared by appropriate dilutions of the concentrated premix or higher diet concentrations.
- Rate of preparation of diet (frequency): Fresh diet was prepared and offered to the animals each week.
- Mixing appropriate amounts with (Type of food): Ground Purina Certified Rodent Chow # 5002
- Storage temperature of food: Diets were stored in polypropylene containers at room temperature. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Experimental diets were analyzed for stability, homogeneity and concentration of test substance in the diet by using liquid chromatography.
- Homogeneity studies performed on samples from all dietary concentrations indicated that test substance was uniformly distributed in the diet.
- Stability studies were conducted on diets (8000 and 100 ppm) stored at room temperature in closed polypropylene containers and in glass jars. These analyses indicated that the test substance was stable in the diets for at least 21 d under both storage conditions for all dose levels.
- Concentration verification analyses revealed that the test substance concentrations were 90.7 to 111.8% of nominal for all 5 concentrations. - Duration of treatment / exposure:
- 95 and 96 days for males and females, respectively.
- Frequency of treatment:
- Daily
- Remarks:
- Doses / Concentrations:
0, 100, 500, 1000, 4000 or 8000 ppm (equivalent to 0, 6, 31 and 62 mg/kg bw/day (males) and 0, 8, 38 and 77 mg/kg bw/day (females). [Due to mortality in the 4000 and 8000 ppm treatment groups, the corresponding daily intakes could not be calculated.]
Basis: nominal in diet - No. of animals per sex per dose:
- 15
- Control animals:
- yes, plain diet
- Details on study design:
- - Rationale for animal assignment: Animals were assigned to test groups, based on body weight, by a computer generated, weight stratified randomization procedure. Only rats with body weights within ± 20% of the population mean for each sex were used in the study.
Assignment of animals: The animals were assigned into following groups in the study:
- Group 1(Diet control): Plain diet
- Group 2: 100 ppm test substance in diet
- Group 3: 500 ppm test substance in diet
- Group 4: 1000 ppm test substance in diet
- Group 5: 4000 ppm test substance in diet
- Group 5: 8000 ppm test substance in diet - Observations and examinations performed and frequency:
- MORTALITY and CLINICAL SIGNS: Yes
- Time schedule: Twice daily
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Animals were observed once a week for detailed clinical observations, and six days a week for overt clinical signs.
BODY WEIGHT: Yes
- Time schedule for examinations: Body weight data were collected weekly for all animals.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes, food consumption data were collected weekly for all animals.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Ophthalmic examinations were performed prior to treatment and prior to final sacrifice.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Just prior to sacrifice at study termination
- Anaesthetic used for blood collection: Yes (methoxyflurane)
- Animals fasted: Yes, overnight
- How many animals: Blood samples were collected from 10 animals/sex/group (or from the surviving animals in the 4000 ppm group) for haematology analyses.
- Parameters checked: Hemoglobin, hematocrit, erythrocyte count, erythrocyte indices, platelet count, total leukocyte count, differential leukocyte count, reticulocyte count
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Just prior to sacrifice at study termination
- Animals fasted: Yes, overnight
- How many animals: Blood samples were collected from 10 animals/sex/group for clinical chemistry
- Parameters checked: AST (SGPT), ALT (SGOT), creatinine, alkaline phosphatase, gamma glutamyl transpeptidase, glucose, urea nitrogen, total protein, albumin, globulin, A/G ratio, total bilirubin, direct bilirubin, indirect bilirubin, calcium, phosphorous, sodium, potassium, chloride
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- SACRIFICE: Animals were anesthetized with methoxyflurane and exsanguinated by severing the brachial vessel.
GROSS PATHOLOGY: Yes, all animals (surviving) were subject to gross necropsy.
HISTOPATHOLOGY: Yes, histopathologic examinations were performed on selected tissues from 10 randomly selected animals/group from the control and 1000 ppm dose groups. The 1000 ppm group was selected for complete examination because it was the highest dose group without significant mortality.
- Tissues collected for histopathology: Gross lesions, brain, eyes, pituitary, salivary gland, heart, aorta, thymic region, thyroid, lungs, adrenals, trachea, esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, spinal cord, pancreas, liver, kidneys, urinary bladder, testes, prostate, epididymis, ovaries, uterus, spleen, lymph nodes, sciatic nerves, sternum - Other examinations:
- ORGAN WEIGHT: Prior to sacrifice, body weights were obtained to allow expression of relative organ weights. The liver, spleen, kidney, heart, brain, adrenals, testes and ovaries were weighed for all animals.
- Statistics:
- - Parametric variables were compared between the dose and control groups using Levene’s test for homogeneity of variances, by analysis of variance and by pooled variance t-tests.
- Non-parametric data were analyzed by the Kruskal-Wallis test or by the Wilcoxon rank sum test as modified by Mann-Whitney.
- Frequency data were compared using Fisher’s exact tests. - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- All animals in the 8000 ppm group died. For the 4000 ppm group 12/15 males and 11/15 females died or were sacrificed in a moribund condition.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Treatment-related clinical findings were restricted to animals from the 4000 and 8000 ppm groups. The observations were of two types, general cachexia and loose faeces. Findings for the surviving animals were similar to those that died.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Decrease in body weight was observed for the 4000 and 8000 ppm dose group surviving the first week of the study. A slight but significant decrease was also noticed in the males of the 1000 ppm dose group.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Decrease in food consumption was observed for the 4000 and 8000 ppm dose group surviving the first week of the study. A slight decrease in the food consumption was also noticed in the males of the 1000 ppm dose group.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related finding at any treatment level was observed.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- No treatment related change was observed for males or females from any treatment group (4000 ppm or lower).
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- No treatment related effect up to 1000 ppm. Significant increases in ALT and phosphorus were observed for 3 surviving males of the 4000 ppm group.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- No treatment related effect up to 1000 ppm was observed.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- No treatment related effect up to 1000 ppm was observed. Gross lesions related to the treatment were restricted to the animals that died in the 8000 and 4000 ppm group and to a lesser degree in the animals that survived the 4000 ppm group. The findings were fecal staining of perineal area, emaciation, colour changes of the organs, ileus consisting of distended fluid and gas-filled viscera.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Histopathologic changes were observed for animals in the 4000 and 8000 ppm dose group and consisted of congestion of various organs or tissues, mucosal cell degeneration of the villus tips of small intestine and cecum, submucosal edema of stomach, splenic contraction and hepatocellular atrophy.
- Histopathological findings: neoplastic:
- not examined
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 31 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: the dose of 500 ppm is equivalent to 31 mg/kg bw/day for males and 38 mg/kg bw/day for females
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 38 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: the dose of 500 ppm is equivalent to 31 mg/kg bw/day for males and 38 mg/kg bw/day for females
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 62 mg/kg bw/day (nominal)
- System:
- other: GI tract, hepatobiliary and spleen (males)
- Organ:
- colon
- ileum
- intestine
- liver
- spleen
- stomach
- Treatment related:
- yes
- Dose response relationship:
- yes
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 77 mg/kg bw/day (nominal)
- System:
- other: GI tract, hepatobiliary and spleen (females)
- Organ:
- colon
- ileum
- intestine
- liver
- spleen
- stomach
- Treatment related:
- yes
- Dose response relationship:
- yes
- Conclusions:
- Based on the results of the read across substance study, the NOAEL for the test substance is considered to be 500 ppm in the diet, i.e., equivalent to 31 mg/kg bw/d (i.e. 25 mg a.i./kg bw/d) for males and 38 mg/kg bw/d (i.e. 30 mg a.i./kg bw/d) for females.
- Executive summary:
A study was conducted to determine the repeated dose oral toxicity of the read across substance, C12-16 ADBAC (active ingredient: approx. 80%), according to OECD Guideline 408 and US EPA OPP 82 -1, in compliance with GLP. This sub-chronic oral toxicity study (90 d) was realised in Sprague-Dawley rats. The rats were administered daily dietary levels of 0, 100, 500, 1000, 4000 and 8000 ppm test substance, equivalent to 0, 6, 31 and 62 mg/kg bw/d (i.e. 0, 4.8, 25 and 50 mg a.i./kg bw/d) (males) and 0, 8, 38 and 77 mg/kg bw/d (i.e. 0, 6.4, 30 and 62 mg a.i./kg bw/d) (females) for 95 and 96 days, respectively. Daily intakes at 4000 and 8000 ppm could not be calculated due to high mortality. The animals were observed for mortality, clinical signs, body weight, food consumption, hematology and clinical chemistry at termination. Gross and histopathological examinations were also performed. A slight trend in reduction of body weight and food consumption in males at 1000 ppm was observed. Besides this, there were no treatment-related findings at 1000 ppm or lower. There was 80 and 100% mortality at 4000 and 8000 ppm, respectively. Clinical signs of toxicity (general cachexia and loose faeces), decreased food consumption and body weights, gross necropsy findings (including increased amounts of liquids or semi-solid material within the stomach, jejunum, ileum and cecum) were also observed at 4000 and 8000 ppm. The cause of morbidity and death was assumed to be shock secondary to fluid and/or ionic shifts in the gastro-intestinal tract. Under study conditions, the NOAEL for the C12 -16 ADBAC was considered to be 500 ppm in the diet, i.e., equivalent to 31 mg/kg bw/d (i.e. 25 mg a.i./kg bw/d) for males and 38 mg/kg bw/d (i.e. 30 mg a.i./kg bw/d) for females (Van Miller, 1988). Based on the results of the read across substance study, the NOAEL for the test substance, C14 ADBAC, can be considered to be 500 ppm in the diet, i.e., equivalent to 31 mg/kg bw/d (i.e. 25 mg a.i./kg bw/d) for males and 38 mg/kg bw/d (i.e. 30 mg a.i./kg bw/d) for females.
Reference
Other than a slight trend in reduced body weight and food consumption in males at 1000 ppm, there were no treatment-related findings at 1000 ppm or less. The highest dose of the test substance lead to 100 and 80% mortality for 8000 and 4000 ppm group respectively indicating 1000 ppm to be the maximal tolerated dose. The animals that survived at 4000 ppm were cachectic and debilitated. The probable cause of death was ileus and shock. The females showed less aberrations in all measurements than the males.
Mortality at high doses was considered to occur at concentrations gastrointestinal mucosa and resulting in dehydration and wasting or affects the gastrointestinal flora. The observed effects were all related to the irritation and corrosivity properties of the substance and no specific organ toxicity was evidenced. The NOEL of the study was based on reduction in body weight and body weight gain, consistent with decreased food consumption. Therefore, it was concluded that all effects could be attributed to local gastrointestinal irritaton/corrosion and consequent reduced food intake without observing any primary systemic effect.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 25 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Guideline compliant study
- System:
- other: no primary systemic effects observed
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
- Reason / purpose for cross-reference:
- data waiving: supporting information
- Reason / purpose for cross-reference:
- data waiving: supporting information
- Reason / purpose for cross-reference:
- data waiving: supporting information
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- March 06, 1972
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- A study was conducted to determine the short term repeated dose dermal toxicity of the test substance following application of 1 mL/kg bw (i.e., equivalent to 0.8 mg/kg bw/day) and 4 mL/kg bw (i.e., equivalent to 3.2 mg/kg bw/day) of the test solution in rabbits for 20 days.
- GLP compliance:
- no
- Limit test:
- no
- Specific details on test material used for the study:
- 8 oz jar containing a white powder
Lot no.: 263-S
Test substance: Myristyl dimethyl benzyl ammonium chloride
Purity: 99.1%
Dilution of 800 ppm in water was made, based on a 100% active material and used in test - Species:
- rabbit
- Strain:
- not specified
- Sex:
- male/female
- Type of coverage:
- occlusive
- Vehicle:
- water
- Details on exposure:
- TEST SITE
- Area of exposure: Backs and flanks
- % coverage: 10% of total body area
- Type of wrap if used: Rubberized fabric
- Time intervals for shavings or clipplings: Hair was clipped from their backs and flanks. One half of each test area was abraded as required, while the remainder was left intact
REMOVAL OF TEST SUBSTANCE
- Washing (if done): No washing
- Time after start of exposure: 27 days
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 1 mL/kg (0.8 mg/kg bw/day) and 4 mL/kg (3.2 mg/kg bw/day)
- Constant volume or concentration used: Yes - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- Dose groups:
1 mL/kg = 0.8 mg/kg bw/day
4 mL/kg = 3.2 mg/kg bw/day - Duration of treatment / exposure:
- 20 d
- Frequency of treatment:
- once a day
- No. of animals per sex per dose:
- 1 animal per sex per dose
- Control animals:
- yes
- Observations and examinations performed and frequency:
- Food, fluid intake, excretions, behavior and appearance of the animals were observed daily. The animals were weighed, as required. Blood and urine studies were performed at the beginning of the test, at the 20 d interval end prior to autopsy.
- Sacrifice and pathology:
- At autopsy, gross findings were made and tissues retained for histological examination.
- Clinical signs:
- not examined
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- Minimal erythema was observed in the treated rabbits on day 5, with minimal edema evident on day 9 in the animals receiving the larger dose. In the same group the erythema became more pronounced on day 11, and persisted with minimal edema at those levels through the rest of the treatment interval. At the lower dose level (1 mL/kg bw) minimal hyperemia showed occasional correction with no edema. On day 15 in the same group hyperemia increased slightly in intensity, but became minimal on day 19 and remained that way to day 21. Minimal edema was observed in the 1 mL/kg bw animals on day 17 through the end of treatment. In the control rabbits minimal hyperemia was observed in the rabbits from day 11 through day 21. All rabbits showed complete recovery of dermal irritation within 4 days after cessation of treatment.
- Mortality:
- not examined
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Weights increases were normal.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food intake was all within normal parameters at all times.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- Water intake was all within normal parameters at all times.
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Hematology studies were all within normal parameters at all times.
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Description (incidence and severity):
- Urine analysis studies were all within normal parameters at all times.
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- At no time did any of the rabbits manifest abnormal behavior or appearance.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Gross findings at autopsy were not significant.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- The histological findings in the treated rabbits were identical to those in the controls.
- Histopathological findings: neoplastic:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- Sysmetic toxicity
- Effect level:
- ca. 3.2 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- behaviour (functional findings)
- body weight and weight gain
- food consumption and compound intake
- gross pathology
- haematology
- histopathology: non-neoplastic
- urinalysis
- water consumption and compound intake
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- ca. 0.8 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- dermal irritation
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 0.8 mg/kg bw/day
- System:
- integumentary
- Organ:
- skin
- Treatment related:
- yes
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
- Conclusions:
- Under study conditions, NOAEL for systemic effects and LOAEL for dermal irritation (local effect) were considered to be 3.2 mg/kg bw/day and 0.8 mg/kg bw/day respectively.
- Executive summary:
A study was conducted to determine the short term repeated dose dermal toxicity of the test substance, C14 ADBAC (Purity 99.1%), according to the procedure described in Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics, published by the Association of Food and Drug Officials of the United States. In the study, 1 mL/kg bw (i.e., equivalent to 0.8 mg/kg bw/day) and 4 mL/kg bw (i.e., equivalent to 3.2 mg/kg bw/day) of the 800 PPM solution of the test substance were applied over 10% of the total body surface (Hair clipped back and flank) of the rabbits (one rabbit per sex per dose level) for 20 days. After each application of test substance the torsos of the test animals were wrapped with a rubberized fabric to prevent grooming by the rabbits with possible inhalation or ingestion of test product. Survivors were maintained for two weeks after the last application when all animals were autopsied, as required by the reference. Food, fluid intake, excretions, behaviour and appearance of the animals were observed daily. The animals were weighed, as required. Blood and urine studies were performed at the beginning of the test, at the 20 d interval end prior to autopsy. At autopsy, gross findings were made and tissues retained for histological examination. At no time did any of the rabbits manifest abnormal behaviour or appearance. Food and water intake, excretions, blood and urine studies were all within normal parameters at all times. Weights increases were normal. Minimal erythema was observed in the treated rabbits on day 5, with minimal edema evident on day 9 in the animals receiving the larger dose. In the same group the erythema became more pronounced on day 11, and persisted with minimal edema at those levels through the rest of the treatment interval. At the lower dose level (1 mL/kg bw = 0.8 mg/kg bw/day) minimal hyperemia showed occasional correction with no edema. On Day 15 in the same group hyperemia increased slightly in intensity, but became minimal on Day 19 and remained that way to Day 21. Minimal edema was observed in the 1 mL/kg bw animals on Day 17 through the end of treatment. In the control rabbits minimal hyperemia was observed in the rabbits from day 11 through Day 21. All rabbits showed complete recovery of dermal irritation within 4 d after cessation of treatment. Gross findings at autopsy were not significant. The histological findings in the treated rabbits were identical to those in the controls. Under study conditions, NOAEL for systemic effects and LOAEL for dermal irritation (local effect) were considered to be 3.2 and 0.8 mg/kg bw/day respectively (Luy and Frances, 1972).
Reference
Table 1: Histopathology results
Rabbit |
Dose 800 ppm |
Findings |
1 F |
1 mL/kg |
As in control |
2 M |
1 mL/kg |
As in control |
3 F |
4 mL/kg |
As in control |
4 M |
4 mL/kg |
As in control |
5 F |
4 mL/kg |
Water control |
6M |
4 mL/kg |
Water control |
Dose groups:
1 mL/kg = 0.8 mg/kg bw/day
4 mL/kg = 3.2 mg/kg bw/day
Table 2: Dermal reactions 24 h after each set of applications
Day of treatment |
|
1F |
2M |
3F |
4M |
5F* |
6M* |
2 |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
|
Edema |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
|
Edema |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
|
Edema |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
Erythema |
0 |
0 |
0 |
1 |
0 |
0 |
|
Edema |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
Erythema |
1 |
0 |
1 |
1 |
0 |
0 |
|
Edema |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
Erythema |
1 |
0 |
1 |
1 |
0 |
0 |
|
Edema |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
Erythema |
1 |
1 |
1 |
1 |
0 |
0 |
|
Edema |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
Erythema |
1 |
1 |
1 |
1 |
0 |
0 |
|
Edema |
0 |
0 |
0 |
1 |
0 |
0 |
10 |
Erythema |
0 |
1 |
2 |
2 |
0 |
0 |
|
Edema |
0 |
0 |
0 |
1 |
0 |
0 |
11 |
Erythema |
1 |
1 |
2 |
2 |
1 |
1 |
|
Edema |
0 |
0 |
0 |
1 |
0 |
0 |
12 |
Erythema |
0 |
0 |
2 |
2 |
1 |
1 |
|
Edema |
0 |
0 |
1 |
1 |
0 |
0 |
13 |
Erythema |
0 |
0 |
2 |
2 |
1 |
1 |
|
Edema |
0 |
0 |
1 |
1 |
0 |
0 |
14 |
Erythema |
0 |
0 |
2 |
2 |
0 |
1 |
|
Edema |
0 |
0 |
1 |
1 |
0 |
0 |
15 |
Erythema |
0 |
0 |
2 |
2 |
0 |
1 |
|
Edema |
0 |
0 |
1 |
1 |
0 |
0 |
16 |
Erythema |
0 |
0 |
2 |
2 |
0 |
1 |
|
Edema |
0 |
0 |
1 |
1 |
0 |
0 |
17 |
Erythema |
0 |
0 |
2 |
2 |
0 |
1 |
|
Edema |
0 |
0 |
1 |
1 |
0 |
0 |
18 |
Erythema |
0 |
0 |
2 |
2 |
0 |
1 |
|
Edema |
0 |
0 |
1 |
1 |
0 |
0 |
19 |
Erythema |
1 |
1 |
2 |
2 |
0 |
1 |
|
Edema |
1 |
1 |
1 |
1 |
0 |
0 |
20 |
Erythema |
1 |
1 |
2 |
2 |
1 |
1 |
|
Edema |
1 |
1 |
1 |
1 |
0 |
0 |
21 |
Erythema |
1 |
1 |
2 |
2 |
1 |
1 |
|
Edema |
1 |
1 |
1 |
1 |
0 |
0 |
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Oral
A 90 d study was conducted to determine the repeated dose oral toxicity of the read across substance, C12-16 ADBAC (active ingredient: approx. 80%), in Sprague Dawley rats, according to OECD Guideline 408 and US EPA OPP 82 -1, in compliance with GLP. In this study, the rats were administered daily dietary levels of 0, 100, 500, 1000, 4000 and 8000 ppm test substance, equivalent to 0, 6, 31 and 62 mg/kg bw/d (i.e. 0, 4.8, 25 and 50 mg a.i./kg bw/d) (males) and 0, 8, 38 and 77 mg/kg bw/d (i.e. 0, 6.4, 30 and 62 mg a.i./kg bw/d) (females) for 95 and 96 days, respectively. Daily intakes at 4000 and 8000 ppm could not be calculated due to high mortality. The animals were observed for mortality, clinical signs, body weight, food consumption, hematology and clinical chemistry at termination. Gross and histopathological examinations were also performed. Other than a slight trend in reduced body weight and food consumption in males at 1000 ppm, there were no treatment-related findings at 1000 ppm or less. The highest dose of the test substance lead to 100 and 80% mortality for 8000 and 4000 ppm group respectively indicating 1000 ppm to be the maximal tolerated dose. The animals that survived at 4000 ppm were cachectic and debilitated. The probable cause of death was assumed to be shock secondary to fluid and/or ionic shifts in the gastro-intestinal tract, which was attributed to irritation and corrosivity properties of the substance. The females showed less aberrations in all measurements than the males. Based on the decreased food consumption and body weights at 1000 ppm, the NOEL for the test substance was established at 500 ppm in the diet, i.e., equivalent to 31 mg/kg bw/d (i.e. 25 mg a.i./kg bw/d) for males and 38 mg/kg bw/d (i.e. 30 mg a.i./kg bw/d) for females (Van Miller, 1988).
Additional sub-chronic (i.e., 8-week study in dogs, 93 dose range finding study in mice) and chronic dietary studies (i.e., 1-year study in dogs and 2-year study in rats) available with the read across substance, resulted in respective NOELs at 800 ppm in dogs (i.e., 27.4-34.3 mg/kg bw/day or 21.92-27.44 mg a.i./kg bw/day), 500 ppm in mice (i.e., 85-102 mg/kg bw/day or 68-81.6 mg a.i./kg bw/day), 400 ppm in dogs (i.e., 13.1-14.6 mg/kg bw/day or 24.8-30.4 mg a.i./kg bw/day) and 1000 ppm in rats (i.e., NOAEL = 44-57 mg/kg bw/day or 35.2-45.6 mg a.i./kg bw/day). Considering that the effects on which the NOEL derivation could have been based, independently on the species tested, was the reduction in body weight and body weight gain, consistent with decreased food consumption. It was concluded that all effects could be attributed to local gastrointestinal irritaton/corrosion and consequent reduced food intake without observing any primary systemic effect. Therefore, the derivation of a NOAEL for systemic effects was deemed inappropriate (Biocides assessment report, 2015).
Dermal
A study was conducted to determine the short term repeated dose dermal toxicity of the test substance, C14 ADBAC (purity: 99.1%), according to the procedure described in Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics, published by the Association of Food and Drug Officials of the United States. In the study, 1 mL/kg bw (i.e., equivalent to 0.8 mg/kg bw/day) and 4 mL/kg bw (i.e., equivalent to 3.2 mg/kg bw/day) of the 800 PPM solution of the test substance were applied over 10% of the total body surface (Hair clipped back and flank) of the rabbits (one rabbit per sex per dose level) for 20 days. After each application of test substance the torsos of the test animals were wrapped with a rubberized fabric to prevent grooming by the rabbits with possible inhalation or ingestion of test product. Survivors were maintained for two weeks after the last application when all animals were autopsied, as required by the reference. Food, fluid intake, excretions, behaviour and appearance of the animals were observed daily. The animals were weighed, as required. Blood and urine studies were performed at the beginning of the test, at the 20 d interval end prior to autopsy. At autopsy, gross findings were made and tissues retained for histological examination. At no time did any of the rabbits manifest abnormal behaviour or appearance. Food and water intake, excretions, blood and urine studies were all within normal parameters at all times. Weights increases were normal. Minimal erythema was observed in the treated rabbits on day 5, with minimal edema evident on day 9 in the animals receiving the larger dose. In the same group the erythema became more pronounced on day 11, and persisted with minimal edema at those levels through the rest of the treatment interval. At the lower dose level (1 mL/kg bw = 0.8 mg/kg bw/day) minimal hyperemia showed occasional correction with no edema. On Day 15 in the same group hyperemia increased slightly in intensity, but became minimal on Day 19 and remained that way to Day 21. Minimal edema was observed in the 1 mL/kg bw animals on Day 17 through the end of treatment. In the control rabbits minimal hyperemia was observed in the rabbits from day 11 through Day 21. All rabbits showed complete recovery of dermal irritation within 4 d after cessation of treatment. Gross findings at autopsy were not significant. The histological findings in the treated rabbits were identical to those in the controls. Under study conditions, NOAEL for systemic effects and LOAEL for dermal irritation (local effect) were considered to be 3.2 and 0.8 mg/kg bw/day respectively (Luy and Frances, 1972).
Justification for classification or non-classification
Based on the observed effects and available NOAELs in 90-day oral study together with other sub-chronic and chronic studies with read across substance, it can be concluded that C14 ADBAC does not require classification for STOT RE according to CLP criteria (Regulation EC 1272/2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.